Chardan Capital Forecasts Krystal Biotech FY2026 Earnings

Krystal Biotech, Inc. (NASDAQ:KRYS) – Research analysts at Chardan Capital cut their FY2026 earnings estimates for Krystal Biotech in a research report issued to clients and investors on Wednesday, May 7th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings of $8.80 per share for the year, down from their prior estimate of $9.13. Chardan Capital currently has a “Buy” rating and a $219.00 price target on the stock. The consensus estimate for Krystal Biotech’s current full-year earnings is $6.14 per share.

KRYS has been the subject of a number of other reports. Guggenheim lowered their price objective on Krystal Biotech from $195.00 to $189.00 and set a “buy” rating for the company in a research report on Wednesday. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Jefferies Financial Group began coverage on shares of Krystal Biotech in a report on Wednesday, March 5th. They issued a “buy” rating and a $245.00 price objective on the stock. Citigroup boosted their target price on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research note on Thursday, February 20th. Finally, HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 6th. One analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $218.63.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $132.23 on Friday. The company has a market cap of $3.82 billion, a price-to-earnings ratio of 44.22 and a beta of 0.79. The stock’s 50-day moving average is $171.56 and its two-hundred day moving average is $170.04. Krystal Biotech has a 1-year low of $131.71 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 EPS for the quarter, missing the consensus estimate of $1.38 by ($0.18). The business had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Kathryn Romano sold 750 shares of the company’s stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at approximately $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Fifth Third Bancorp grew its holdings in shares of Krystal Biotech by 159.1% during the first quarter. Fifth Third Bancorp now owns 171 shares of the company’s stock worth $31,000 after buying an additional 105 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new stake in Krystal Biotech during the 3rd quarter worth approximately $40,000. GF Fund Management CO. LTD. purchased a new position in shares of Krystal Biotech in the 4th quarter valued at approximately $95,000. GAMMA Investing LLC increased its holdings in shares of Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company’s stock valued at $121,000 after purchasing an additional 432 shares during the period. Finally, Covestor Ltd raised its stake in shares of Krystal Biotech by 972.7% during the fourth quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after purchasing an additional 642 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).